secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-174458
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M
---------------------------------------------------------------------------

- Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).
- Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.
- Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.
- Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.
- MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/0001193125-25-174458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/d88313d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer